A new frontier in liver disease: A monthly injection for MASH
A phase 2 clinical trial published in The Lancet Gastroenterology & Hepatology reports promising early results for efimosfermin alfa as a potential once-monthly treatment for metabolic dysfunction-associated steatohepatitis (MASH). Researchers led by Mazen Noureddin conducted a randomized, placebo-controlled study involving adults with biopsy-confirmed MASH and significant fibrosis. Participants received either a 300 mg subcutaneous dose of the investigational drug or a placebo once a month for 24 weeks. The primary focus of this trial was to evaluate the safety and tolerability profile of the treatment, monitoring for adverse events, vital sign changes, and significant laboratory abnormalities. This development represents a significant step toward a more convenient therapeutic regimen for a complex liver condition with limited treatment options.
Study Significance: For pulmonologists managing patients with complex comorbidities, understanding advancements in hepatology is crucial, particularly for conditions like MASH that can impact systemic inflammation and overall patient health. This research highlights a shift towards less frequent, more manageable dosing schedules, a concept highly relevant to chronic disease management across specialties, including chronic obstructive pulmonary disease (COPD) and asthma. The methodological rigor of this randomized controlled trial sets a benchmark for evaluating novel biologics and their long-term safety in treating progressive fibrotic diseases.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
